

About Deep Pharma Intelligence

Deep Pharma Intelligence (DPI) is a leading UK-based strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, and Healthcare Tech industries.

Deep Pharma Intelligence is a joint venture created by **Deep Knowledge Analytics Pharma Division** and **BPT Analytics (BiopharmaTrend)** – two highly specialized think tanks in the area of biotech innovation profiling, business intelligence, and biotech investment advisory. The company is dedicated to producing powerful data mining and visualization systems, interactive analytics tools, and industry reports offering deep technical insights, business intelligence, and strategic guidance in the high growth and significant opportunity areas of the pharmaceutical industry, including artificial intelligence (AI) in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

Our Value Proposition:

Open Access and Proprietary Reports

Deep Pharma Intelligence is producing regular open access reports covering emerging bio-pharmaceutical markets – technologies, innovations, companies, and trends.

Our clients and partners can enjoy access to proprietary reports, featuring additional in-depth research conducted by our team on regular basis.

IT-Platform and Big Data Analytics Dashboard

Our company is building a sophisticated cloud-based engine for advanced market and business intelligence in the pharmaceutical and healthcare industries. It includes data mining engine, infrastructure for expert data curation, and advanced visualization dashboards, including mindmaps, knowledge graphs, and 3-dimensional visualizations.

Visit our prototype dashboard to learn more:
<https://www.deep-pharma.tech/dashboard>

Strategic Consulting and Investment Advisory

Deep Pharma Intelligence offers a comprehensive range of consulting services, including comprehensive support for growth and investment decision making in the bio-pharmaceutical industry and related areas. It includes a wide range of services from market and competitor research, technology scouting and due diligence, to investment landscape profiling and comprehensive analytics support for investment decision-making.




Investment Digest “AI in Pharma Publicly Traded Companies 2021”

Based on the chapter 'Publicly Traded Companies' in the 130-page industry report "[AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020](#)", the Digest is an overview of the publicly traded part of the pharmaceutical AI sector, including 13 AI-driven pharma public companies and one company with upcoming IPO across the globe.

Also, exclusively, this report has an additional chapter called '**Portfolio Analysis**' This part includes **four different investment strategies** for AI-driven pharma company stocks, depending on the portfolio's riskiness.


Some of the key takeaways from this digest include:

- The segment of pharmaceutical AI continues consolidation;
- Pharmaceutical AI sector is “heating up” for investments;
- Big pharma and contract research organizations increasingly compete for AI partnerships;
- The sector of pharmaceutical AI is maturing for a likely wave of IPOs and M&As in 2021-2022;
- COVID-19 pandemics appears to be a positive catalyst for the acceleration of the AI adoption.




- Number of corporations
- Number of AI companies
- Number of investors

Industry Growth



AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape / 2020



AI in Pharma Stock Indices

- Equal Weights
- Weights by Capitalization
- Min Variance Portfolio
- Sharpe Ratio Portfolio

